This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

JAMA. 2001;286:3073-3074.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 2001;50:1038-41

2 tables omitted

Live attenuated varicella vaccine (Var) is recommended in the United States for children aged 12-18 months and for susceptible older children, adolescents, and adults.¹ The Advisory Committee on Immunization Practices recommends that Var be administered either simultaneously with measles-mumps-rubella (MMR) vaccine or separately by 30 days.¹ This report summarizes an evaluation of these recommendations, which found that a decrease in Var effectiveness occurred when Var was administered <30 days after MMR; therefore, as currently recommended, physicians should administer Var simultaneously with MMR or wait at least 30 days if the vaccines are administered separately.

Using the Vaccine Safety Datalink (VSD) project, the effectiveness of Var was assessed when administered simultaneously with or within 30 days of administering MMR; diphtheria and tetanus toxoids and pertussis vaccine (DTP); Haemophilus influenzae type B vaccine (Hib); oral poliovirus vaccine (OPV); inactivated poliovirus vaccine (IPV); and hepatitis B vaccine (HepB). . . . [Full Text of this Article]